A Clinical Practice Guideline for the Management of Pregnancy Alloimmunized to Red Blood Cell Antigens
Authors:
- 3 November 2025
- journal article
- practice guideline
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (11) , e2544649
Abstract
Importance: Red blood cell alloimmunization is typically associated with the transplacental transfer of incompatible fetal red blood cells into maternal circulation. Subsequent pregnancies can be affected by fetal anemia, hydrops fetalis, and perinatal death. Most cases of Rhesus D (RhD) alloimmunization due to pregnancy can be prevented by the proper administration of Rhesus immune globulin. However, an emerging practice of using low-titer, O, RhD-positive whole blood (LTOWB) in cases of life-threatening hemorrhage has the potential to increase the exposure of the female population to a new source of incompatible red blood cells. Objective: To establish recommendations for the management of the red blood cell alloimmunized pregnancy. Evidence: Four working groups were assembled that included experts in (1) trauma and transfusion medicine, (2) hematology, (3) maternal-fetal medicine/obstetrics, and (4) neonatology. Patient stakeholders and ethics representatives were included in each working group. The patient/problem, intervention, comparison, outcome (PICO) framework was used to identify key clinical knowledge gaps. Library scientists at Johns Hopkins University performed systematic reviews and meta-analyses on these topics and provided final reports to the working groups. All 4 working groups participated in a Delphi process to refine recommendations and practice points for each PICO question that reflected consideration of the following factors: balance of benefits and harms; certainty of evidence; values and preferences; resource use and costs; ethics; equity; and feasibility. Findings: Seven clinical recommendations and 32 practice points were developed by the maternal-fetal medicine/obstetrics working group. Recommendations included the following: use of cell-free fetal DNA to identify the at-risk fetus early in pregnancy, followed by immunomodulation with intravenous immune globulin (IVIG) in select cases; the implementation of middle cerebral artery peak systolic velocity Doppler measurements to detect fetal anemia earlier in pregnancy; the use of IVIG in patients with a documented antigen-positive fetus with a history of either fetal anemia or a fetal loss due to hemolytic disease of the fetus and newborn before 24 weeks’ gestational age in a previous pregnancy; the continuation of intrauterine transfusion therapy until the end of the 35th week of pregnancy; and prolonging gestational age to between 37 weeks 0 days and 38 weeks 6 days before proceeding to delivery. Conclusions and Relevance: These recommendations provide an updated approach to the management of red blood cell alloimmunized pregnancies. The lack of high-quality evidence limits the strength of the recommendations but points to the need for a standardized approach to this rare disease.Keywords
This publication has 79 references indexed in Scilit:
- Variations and Opportunities in Postnatal Management of Hemolytic Disease of the Fetus and NewbornJAMA Network Open, 2025
- Critical procedural steps in intrauterine transfusion: Delphi survey of international expertsUltrasound in Obstetrics & Gynecology, 2025
- Assessment of Fetal Rhesus D and Gender with Cell-Free DNA and Exosomes from Maternal BloodReproductive Sciences, 2020
- Complications of intrauterine intravascular blood transfusion: lessons learned after 1678 proceduresUltrasound in Obstetrics & Gynecology, 2016
- Fetal RHD Genotyping from Circulating Cell-Free Fetal DNA in Plasma of Rh Negative Pregnant Women in IranIndian Journal of Hematology and Blood Transfusion, 2015
- Anti-D administration in pregnancy for preventing Rhesus alloimmunisation2013
- Circulating cell‐free fetal DNA for the detection of RHD status and sex using reflex fetal identifiersPrenatal Diagnosis, 2012
- Fetal RHD genotype detection from circulating cell‐free fetal DNA in maternal plasma in non‐sensitized RhD negative womenPrenatal Diagnosis, 2011
- High throughput non-invasive determination of foetal Rhesus D status using automated extraction of cell-free foetal DNA in maternal plasma and mass spectrometryArchives of Gynecology and Obstetrics, 2008
- Noninvasive genotyping fetal Kell blood group (KEL1) using cell‐free fetal DNA in maternal plasma by MALDI‐TOF mass spectrometryPrenatal Diagnosis, 2008